1. Kezar Life Sciences Shutters After Four-Month FDA Delay Derails Critical Liver Disease Trial
A four-month regulatory delay from the U.S. Food and Drug Administration (FDA) forced a small biotech company to close its doors, illustrating the precarious path for firms navigating the drug approval process. Kezar Life Sciences had reached a breakthrough agreement with the FDA in February on a clinical trial plan fo...